Table 2. Pooled and individual estimated CRRs (frequentist meta-analysis), ORRs (frequentist meta-analysis), and DRRs (frequentist and Bayesian meta-analysis) for the included studies.

Regimen	Frequentist meta-analysis			Bayesian meta-analysis
	CRR (95% CI)	ORR (95% CI)	DRR (95% CI)	DRR (95% CI)
Rituximab [18]	0.09 (0.03–0.20)	0.31 (0.20–0.46)	0.15 (0.07–0.27)	0.161
Gemcitabine [20]	0.00 (0.00–0.12)	0.20 (0.08–0.39)	0.10 (0.02–0.27)	0.1092
Bendamustine [22]	0.17 (0.04–0.41)	0.44 (0.22–0.69)	0.22 (0.06–0.48)	0.2249
Oxaliplatin [21]	0.09 (0.01–0.29)	0.32 (0.14–0.55)	0.14 (0.03–0.35)	0.1666
Vorinostat [17]	0.06 (0.00–0.27)	0.06 (0.00–0.27)	0.06 (0.00–0.27)	0.04996
Pixantrone [16]	0.20 (0.11–0.31)	0.37 (0.26–0.50)	0.17 (0.09–0.28)	0.1874
Ibrutinib [24]	0.10 (0.04–0.19)	0.25 (0.16–0.36)	0.11 (0.05–0.20)	0.1279
Lenalidomide	0.12 (0.02–0.30) [23] 0.07 (0.03–0.14) [25]	0.27 (0.16–0.42) [19]	0.14 (0.06–0.26) [19]	0.1413
Pooled results	Fixed: 0.12 (0.09–0.15) Random: 0.11 (0.08–0.15)	Fixed: 0.30 (0.25–0.35) Random: 0.30 (0.24–0.36)	Fixed: 0.14 (0.11–0.18) Random: 0.14 (0.11–0.18)	0.1443 (0.1053–0.1873)

Abbreviations: CI, confidence interval; CRR, complete response rate; DRR, durable response rate; ORR, overall response rate.